A small Japanese study published in Diabetes Care revealed intranasal GLP-1 helped recover insulin secretion and inhibit glucagon production in type 2 diabetes patients. Researchers also observed lower glycoalbumin levels and increased 1,5-anhydroglucitol levels in the nasal GLP-1 group, with no marked adverse events. However, the findings warrant further assessment, researchers said.

Related Summaries